This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-18. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
===== Supplemental Offer and Acceptance Program ===== The Supplemental Offer and Acceptance Program (SOAP) is a process for partially matched and fully unmatched applicant through the Match. Previous to the creation of SOAP, applicants were given the opportunity to contact the programs about the open positions in a process informally called "the scramble". This frantic, loosely structured system forced soon-to-be medical school graduates to choose within minutes programs not on their original Match list. In 2012, the NRMP introduced the organized system called SOAP. As part of the transition, Match Day was also moved from the third Thursday in March to the third Friday. The SOAP occurs during Match Week. First the applicants eligible for SOAP, are informed they did not secure a Match position on the Monday of Match Week. The locations of remaining unfilled residency positions are released to the unmatched applicants the following day. Then programs contact applicants for interviews that usually occur via phone calls. After that, programs prepare lists of applicants and the positions open are offered by each program one at a time to the top applicant on their list. The applicant may accept the offer or reject it. If the offer is rejected it will go to the next applicant in the program list during the next round of SOAP. During Match year 2021 there were four rounds of SOAP.
Phil S. Baran (born August 10, 1977) is a synthetic organic chemist and Professor in the Department of Chemistry at the Scripps Research Institute. His work is focused on synthesizing complex natural products, the development of new reaction methodologies within synthetic organic electrochemistry, and the development of new reagents. He holds several patents and has authored over 300 research articles.
== History == Atomoxetine is manufactured, marketed, and sold in the United States as the hydrochloride salt (atomoxetine HCl) under the brand name Strattera by Eli Lilly and Company, the original patent-filing company and current U.S. patent owner. Atomoxetine was initially intended to be developed as an antidepressant, but it was found to be insufficiently efficacious for treating depression. It was, however, found to be effective for ADHD and was approved by the FDA in 2002, for the treatment of ADHD. Its patent expired in May 2017. On 12 August 2010, Lilly lost a lawsuit that challenged its patent on Strattera, increasing the likelihood of an earlier entry of a generic into the US market. On 1 September 2010, Sun Pharmaceuticals announced it would begin manufacturing a generic in the United States. In a 29 July 2011 conference call, however, Sun Pharmaceutical's Chairman stated "Lilly won that litigation on appeal so I think [generic Strattera]'s deferred." In 2017 the FDA approved the generic production of atomoxetine by four pharmaceutical companies.
== January 26, 1982 (Tuesday) == Prime Minister Mauno Koivisto was elected President of Finland by the 301-member Electoral College, receiving 167 votes. He was sworn in the next day to succeed longtime president Urho Kekkonen. Koivistor had obtained 43% of the popular vote in voting on January 17 and January 18 The government of Israel's Prime Minister Menachem Begin survived a vote of no confidecnce by a margin of 55 to 52 regarding compensation to be paid to Israeli citizens who had settled in the Sinai Peninsula, scheduled to be returned to Egypt after 15 years. U.S. President Ronald Reagan delivered his first State of the Union speech since taking office and proposed "New Federalism", the transfer of administration and control of funding for social programs from the U.S. Department of Health and Human Services to the individual state governments. In India, the popular Tamil language film Vaazhvey Maayam (Life is an Illusion), directed by R. Krishnamoorthy, opened at theaters and would run for almost seven months. The romantic drama starred Kamal Haasan, Sridevi and Sripriya. The "Palace on Wheels", a luxury tourist train operated by Indian Railways and the Rajasthan Tourism Development Corporation, began operations. Born: Mamta Kharab, Indian field hockey player and captain of the women's national team; in Givana, Sonipat district, Haryana state Died: Jean Outland Chrysler, 60, American philanthropist and art collector whose donation of works formed the Chrysler Museum of Art; in Norfolk, Virginia
=== Other nonspecific signs === Some signs that may be present include changes in the nails (such as Muehrcke's lines, Terry's nails, and nail clubbing). Additional changes may be seen in the hands (Dupuytren's contracture) as well as the skin/bones (hypertrophic osteoarthropathy).
Sources: en.wikipedia.org
Progesterone is a progestogen, or an agonist of the nuclear progesterone receptors (PRs), the PR-A, PR-B, and PR-C. In addition, progesterone is an agonist of the membrane progesterone receptors (mPRs), including the mPRα, mPRβ, mPRγ, mPRδ, and mPRϵ. Aside from the PRs and mPRs, progesterone is a potent antimineralocorticoid, or antagonist of the mineralocorticoid receptor, the biological target of the mineralocorticoid aldosterone. In addition to its activity as a steroid hormone, progesterone is a neurosteroid. Among other neurosteroid activities, and via its active metabolites allopregnanolone and pregnanolone, progesterone is a potent positive allosteric modulator of the GABAA receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). The PRs are expressed widely throughout the body, including in the uterus, cervix, vagina, fallopian tubes, breasts, fat, skin, pituitary gland, hypothalamus, and in other areas of the brain. In accordance, progesterone has numerous effects throughout the body. Among other effects, progesterone produces changes in the female reproductive system, the breasts, and the brain. Progesterone has functional antiestrogenic effects due to its progestogenic activity, including in the uterus, cervix, and vagina. The effects of progesterone may influence health in both positive and negative ways. In addition to the aforementioned effects, progesterone has antigonadotropic effects due to its progestogenic activity, and can inhibit ovulation and suppress gonadal sex hormone production.
=== Classification === The crosslinks which bond the polymers of a hydrogel fall under two general categories: physical hydrogels and chemical hydrogels. Chemical hydrogels have covalent cross-linking bonds, whereas physical hydrogels have non-covalent bonds. Chemical hydrogels can result in strong reversible or irreversible gels due to the covalent bonding. Chemical hydrogels that contain reversible covalent cross-linking bonds, such as hydrogels of thiomers being cross-linked via disulfide bonds, are non-toxic and are used in numerous medicinal products. Physical hydrogels usually have high biocompatibility, are not toxic, and are also easily reversible by simply changing an external stimulus such as pH, ion concentration (alginate) or temperature (gelatine); they are also used for medical applications. Physical crosslinks consist of hydrogen bonds, hydrophobic interactions, and chain entanglements (among others). A hydrogel generated through the use of physical crosslinks is sometimes called a 'reversible' hydrogel. Chemical crosslinks consist of covalent bonds between polymer strands. Hydrogels generated in this manner are sometimes called 'permanent' hydrogels. Hydrogels are prepared using a variety of polymeric materials, which can be divided broadly into two categories according to their origin: natural or synthetic polymers. Natural polymers for hydrogel preparation include hyaluronic acid, chitosan, heparin, alginate, gelatin and fibrin.
The hypodermis, otherwise known as the subcutaneous layer, is a layer beneath the skin. It invaginates into the dermis and is attached to the latter, immediately above it, by collagen and elastin fibers. It is essentially composed of a type of cell known as adipocytes, which are specialized in accumulating and storing fats. These cells are grouped together in lobules separated by connective tissue. The hypodermis acts as an energy reserve. The fats contained in the adipocytes can be put back into circulation, via the venous route, during intense effort or when there is a lack of energy-providing substances, and are then transformed into energy. The hypodermis participates, passively at least, in thermoregulation since fat is a heat insulator.
=== Factors determining accuracy === Lupus anticoagulant, a circulating inhibitor predisposing for thrombosis, may skew PT results, depending on the assay used. Variations between various thromboplastin preparations have in the past led to decreased accuracy of INR readings, and a 2005 study suggested that despite international calibration efforts (by INR) there were still statistically significant differences between various kits, casting doubt on the long-term tenability of PT/INR as a measure for anticoagulant therapy. Indeed, a new prothrombin time variant, the Fiix prothrombin time, intended solely for monitoring warfarin and other vitamin K antagonists has been invented and recently become available as a manufactured test. The Fiix prothrombin time is only affected by reductions in factor II and/or factor X and this stabilizes the anticoagulant effect and appears to improve clinical outcome according to an investigator initiated randomized blinded clinical trial, The Fiix-trial. In this trial thromboembolism was reduced by 50% during long-term treatment and despite that bleeding was not increased.
== Overview of the carbon fixation cycles == Seven autotrophic carbon fixation pathways are known: the Calvin Cycle, the Reverse Krebs Cycle, the reductive acetyl-CoA, the 3-HP bicycle, the 3-HP/4-HB cycle, the DC/4-HB cycles, and the reductive glycine pathway.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.